By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Kinaxo Biotechnologies today said that it has entered into a long-term cancer drug screening pact with Japanese pharmaceutical firm Daiichi Sankyo.

Martinsried, Germany-based Kinaxo said that Daiichi Sankyo will use its chemical proteomics technologies Cellular Target Profiling and KinAffinity, as well as its phosphoproteomics technology PhosphoScout in various research programs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.